Carl P Gommoll Selected Research

Levomilnacipran

4/2015	Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
1/2015	Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.
2/2014	A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
1/2014	A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.
1/2014	A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
3/2013	Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl P Gommoll Research Topics

Disease

11	Major Depressive Disorder (Major Depressive Disorders) 01/2018 - 03/2013
2	Anxiety Disorders (Anxiety Disorder) 01/2017 - 01/2016
2	Nausea 02/2014 - 01/2014
1	Dizziness (Lightheadedness) 02/2014
1	Hyperhidrosis 02/2014
1	Hypertension (High Blood Pressure) 02/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 02/2014
1	Vomiting 02/2014
1	Constipation 02/2014
1	Tachycardia (Tachyarrhythmias) 02/2014
1	Headache (Headaches) 01/2014

Drug/Important Bio-Agent (IBA)

6	LevomilnacipranIBA 04/2015 - 03/2013
5	Vilazodone HydrochlorideIBA 01/2018 - 03/2015
2	Serotonin (5 Hydroxytryptamine)IBA 01/2014 - 01/2014
1	Antidepressive Agents (Antidepressants)IBA 01/2018
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2014
1	Serotonin and Noradrenaline Reuptake InhibitorsIBA 01/2014

Therapy/Procedure

1	Secondary Prevention 01/2014